Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant TCH vs ET-H in HER2+ Breast Cancer
NCT02510781Phase 2Unknown
- Sponsor
- 307 Hospital of the People's Liberation Army
- Start
- Jan 2015
- Primary completion
- Dec 2016
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of epirubicin and carboplatin in breast cancer, sponsored by 307 Hospital of the People's Liberation Army. Status: unknown.
02
Drugs
epirubicincarboplatin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02510781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02510781.